INC424

ApprovedSmall molecule

Novartis

INC424 is one of 83 small molecule programs targeting Primary Myelofibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary MyelofibrosisActive, not recruiting

MyelofibrosisActive, not recruiting

Essential ThrombocythemiaActive, not recruiting

Primary MyelofibrosisApproved

Active, not recruiting

MyelofibrosisPhase 1

Active, not recruiting

Essential ThrombocythemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

Ojjaara

GGlaxo Dba Glaxosmithkline

Phase 3

6 2

Vonjo

OOrsoBio, Inc

Phase 3

4 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

3 4

Rytelo

GGeron Corporation

Phase 3

3 5

Best Available Therapy

Novartis

Phase 3

6 6

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 7

Navitoclax

AbbVie

Phase 3

5 8

Cellcept

Roche

Phase 2

5 9

Fludara

Sanofi

Phase 2

5 10

Trexall

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Myelofibrosis1 trial

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Completed· Novartis logo

Novartis·Phase 4·NCT01558739·48 enrolled

Stem Cell Transplant1 trial

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

Completed· Novartis logo

Novartis·Phase 2·NCT03774082·46 enrolled

Safety and Efficacy1 trial

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Completed· Novartis logo

Novartis·Phase 1/2·NCT01787552·50 enrolled

Myelofibrosis1 trial

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Terminated· Novartis logo

Novartis·Phase 1·NCT01730248·63 enrolled

Essential Thrombocythemia1 trial

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

Completed· Novartis logo

Novartis·Phase 3·NCT01493414·2,233 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for INC424. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INC424 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INC424. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

INC424

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Myelofibrosis1 trial

Stem Cell Transplant1 trial

Safety and Efficacy1 trial

Myelofibrosis1 trial

Essential Thrombocythemia1 trial

References

Drug Info

Quick Facts

Related News